Wexford Capital LP Medicinova Inc Transaction History

Wexford Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$7.7 - $10.42 $679,525 - $919,565	-88,250 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.29 - $13.22 $304,657 - $485,835	-36,750 Reduced 29.4%	88,250 $850,000
Q1 2018 May 15, 2018	BUY	$6.6 - $13.91 $825,000 - $1.74 Million	125,000 New	125,000 $1.28 Million

4.83M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $93.2M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.